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ABSTRACT
Introduction: Epidemiological studies on hemophilia in the Brazilian population 
are historically scarce. Despite the continuous effort made by the National Program 
of Inherited Bleeding Disorders to map this condition, little information is available, 
especially on the period prior to program conception. Therefore, the present study 
aims to assess the epidemiological, serological, and clinical characteristics of patients 
with hemophilia in the state of Rio Grande do Sul, Brazil.
Methods: A total of 455 patients had their medical records reviewed from January 1, 
2003 to December 31, 2007.
Results: We observed a remarkable prevalence of hepatitis C virus (HCV) infection 
in patients with both hemophilia A and B, and this prevalence significantly increased 
along with age (p < 0.001). No positive anti-HCV results were observed among children 
younger than 5 years old. There was a significant correlation between the severity 
of hemophilia and the number of arthropathies in all age categories. Considering the 
presence of inhibitors, a significant difference was observed between age groups, 
as older patients had higher inhibitor titers. There was a significant correlation between 
mean coagulation factor consumption and the number of arthropathies in patients 
over 5 years old. 
Conclusions: This profile analysis of patients with hemophilia reflects a gradual 
improvement in treatment safety and efficiency, as well as the need for continued 
investment in this population. 
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INTRODUCTION
Hemophilia A and B are inherited coagulation disorders caused by a 
quantitative deficiency of coagulation factors VIII and IX, respectively. 
Hemophilia is a rare disease, affecting 0.5 to 2 in 10.000 live births of boys 
worldwide1. Treatment costs are markedly high, especially due to the market 
price of coagulation factors, their considerable consumption, and the demand 
for specific training of health workers2. Moreover, disability resulting from 
inadequate treatment can be burdensome both for patients and caregivers.
The treatment of hemophilia in Brazil has evolved considerably in recent 
years. In the 1980s, it mainly consisted in the administration of blood components 
such as cryoprecipitate and fresh frozen plasma. Due to the lack of specific 
screening for transmissible diseases during this period, 60% of patients with 
hemophilia were infected by the human immunodeficiency virus (HIV) and the 
hepatitis C virus (HCV)3. The acquisition and distribution of lyophilized coagulation 
factors started in the 1990s, but were still far from the ideal for treating the 
Brazilian population of patients with hemophilia. This scenario led to a whole 
generation of patients with serious orthopedic conditions due to hemophilic 
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arthropathy. Similarly, viral infections transmitted 
by blood transfusions were significantly prevalent 
among patients with hemophilia3,4. Beginning in the 
2000s, the “Programa de Coagulopatias Hereditárias” 
(National Program of Inherited Bleeding Disorders) 
of the Brazilian Ministry of Health eventually reached 
the acquisition of the internationally recommended per 
capita amount of coagulation factor units; however, 
these factors were still derived from human plasma. 
The risk of shortages due to scarce supplies of 
voluntary blood donations and newly identified infection 
agents, such as prions, remained threats to the proper 
care of these patients. From 2011, the treatment of 
hemophilia in Brazil reached standards of excellence 
with the introduction of prevention programs and the 
acquisition of coagulation factors manufactured through 
recombinant technology, which were exempt from the 
contamination risk brought by biological agents5-7.
The epidemiological information on patients 
with hemophilia in Brazil is still far from adequate8. 
Population-based registries play an important role in 
monitoring and measuring the quality of health care 
services and the outcomes obtained with the proposed 
interventions. The importance of these records for 
the quality of care of patients with hemophilia is 
clearly recognized, as they allow the understanding 
of clinical needs and adequate resource planning. 
The first national registry initiative was the creation, 
in 2002, of the Inherited Bleeding Disorder Program 
database, initially based on electronic spreadsheets. 
Then, the “Hemovida Coagulopatias Web” software 
was developed in 20099. Unfortunately, both initiatives 
were handicapped by insufficient data loading. 
Information on the disease prior to the implementation 
of these initiatives is even more limited.
In the attempt to recover regional epidemiological 
data referring to the period when databases were 
not systematically updated, this study assessed 
characteristics of patients with hemophilia managed 
in a public health care reference center (Hemocentro 
do Rio Grande do Sul – Hemorgs) in the state of 
Rio Grande do Sul (RS), Brazil from 2003 to 2007.
METHODS
Study design and data extraction
This was a retrospective cohort study that 
assessed the medical records of patients diagnosed 
with hemophilia from different regions of the state 
of Rio Grande do Sul between January 1, 2003 and 
December 31, 2007. The enrolled institutions were 
Hemorgs and the Hemostasis Laboratory of the 
Genetics Department at Universidade Federal do Rio 
Grande do Sul (UFRGS). Hemorgs is a health care 
reference center assigned to conduct the Inherited 
Bleeding Disorders Program regionally, in association 
with the State Foundation for Production and 
Research in Health (Fundação Estadual de Produção 
e Pesquisa em Saúde – FEPPS). Hemorgs is an 
exclusive distributor of blood products acquired by 
the Ministry of Health and provides health assistance 
to registered patients. The Hemostasis Laboratory 
of the Genetics Department at UFRGS performs all 
the genetic testing and diagnosis of blood disorders 
in association with Hemorgs.
The date of diagnosis was defined as the date 
of the first confirmatory test (coagulation factor 
VIII or IX activity). Sociodemographic information 
was obtained from medical records. The presence 
of inhibitors and infections related to transfusions 
or coagulation factor infusions was evaluated. 
Therapeutic products such as lyophilized coagulation 
factors (both recombinant and derived from human 
plasma), antifibrinolytic agents, and blood products 
were assessed. Disease severity was categorized 
as defined by the World Federation of Hemophilia: 
mild (clotting factor activity between 5% and 40%), 
moderate (between 1% and 5%), or severe (less 
than 1% of clotting factor activity).
Ethical aspects
The project was approved by the FEPPS Ethics 
Committee.
Statistical analysis
Categorical variables were described as absolute 
and relative frequencies. Continuous variables were 
described as means and standard deviations in 
case of normal distributions, and as medians and 
interquartile ranges if distributed asymmetrically. The 
chi-squared test was used to compare proportions 
and the Spearman’s correlation coefficient was 
applied to verify associations between continuous 
variables. An alpha error < 0.05 was considered 
statistically significant. Analyses were performed on 
SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 455 records were evaluated, of which 
449 had available clinical data. Demographic 
characteristics of the patients can be seen in 
Table 1. Hemophilia A (HA) was more frequent than 
Hemophilia B (HB) (86.5% vs 13.5%). Regarding 
disease severity, the proportions of severe (HA, n = 154; 
HB, n = 23), moderate (HA, n = 77; HB, n = 14), 
and mild (HA, n = 117; HB, n = 17) HA and HB had 
no significant differences (p = 822).
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Positive family history 198 (85.3%)
Legend: SD: standard deviation.
Serological screening for infectious diseases 
was performed in more than 90% of the patients, 
and the main transfusion-transmissible viruses 
were investigated: HIV, HCV, human T-cell leukemia 
virus types 1 and 2 (HTLV 1 and 2), and hepatitis 
B virus (measured through the hepatitis B surface 
antigen [HBsAg] and the hepatitis B core antibody 
[Anti-HBC]). Seropositivity prevalence can be seen 
in Table 2. For comparison purposes, patients were 
divided according to age into the following groups: 
less than 5 years old (yo) (HA, n = 29; HB, n = 2), 5-12 
yo (HA, n = 63; HB, n = 16), 12-18 yo (HA, n = 79; 
HB, n = 12), and more than 18 yo (HA, n = 203; HB, 
n = 30). The prevalence of anti-HCV seropositivity was 
statistically different between age strata, being higher 
(77.8%) in those over 18 yo (p < 0.001; Pearson’s 
chi-squared test). No positive anti-HCV case was 
observed among children younger than 5 yo.
Table 2: Prevalence of viral infections
Markers Number of positive tests (%)
Total number of 
tests
HTLV 1/2 8 (1.9) 419
HBSAg 11 (2.6) 419
HIV 32 (7.7) 418
Anti-HBC 104 (24.9) 418
Anti-HCV 197 (47.0) 419
Legend: HTLV: human T-cell leukemia virus types 1 and 2; HBsAg: 
hepatitis B virus surface antigen; HIV: human deficiency virus; 
Anti-HBC: hepatitis B virus core antibody; Anti-HCV: hepatitis C 
virus antibody.
Considering arthropathies, 197 (52.3%) patients 
with HA and 26 (45.6%) patients with HB presented 
at least one affected joint (p = .35; Pearson’s 
chi-squared test). There was a significant positive 
correlation between disease severity and the number 
of arthropathies (Rho 0.197, p < .001; Spearman’s 
correlation test).
The presence of inhibitors was also evaluated. 
Considering patients with HA, 282 (86.5%) had 
negative titers, 14 (4.3%) had titers between 0.1 and 
0.9 BU (Bethesda unit), 28 (8.6%) presented titers 
between 1 and 5 BU, and 2 (0.6%) had titers of more 
than 5 BU. As for patients with HB, 55 (93.2%) had 
negative titers, 2 (3.4%) had titers between 0.1 and 
0.9 BU, 2 (3.4%) presented titers between 1 and 5 BU 
and none (0%) had titers of more than 5 BU. There 
were no differences in proportion between these 
subgroups (p = .484; Pearson’s chi-squared test). 
When comparing titer values between age groups 
(Table 3), older patients showed significantly higher 
inhibitor titers (p = 0.040).
Table 3: Inhibitor titers by age group


















> 5 1 (3.4) 0
25 
(12.1) 0
n 29 76 99 207 0.04
The median coagulation factor dose used in 
the evaluated patients during the study period was 
19,350 international units (IUs) (interquartile range 
7,875-44,700). We observed a significant correlation 
between mean factor consumption and the number 
of arthropathies in the following age groups: 5-12 yo 
(Rho = .36, p = .002); 12-18 yo (Rho = .48, p < 001), 
and > 18 yo (Rho = .29, p < .001).
DISCUSSION
This study evaluated clinical and epidemiological 
characteristics of patients with hemophilia in the state 
of Rio Grande do Sul, Brazil, in a period marked by 
the scarcity of information regarding their profiles.
We observed an impressively high prevalence of 
HCV infections that increased across age groups. 
These findings revealed that, before the use of 
lyophilized coagulation products, therapeutic safety 
was an important issue. After the implementation of 
the use of these products and for the last 25 years, 
no seroconversion for HIV or HCV has been reported10,11. 
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The seropositivity presented by patients in the 5-18 yo 
age group is likely to be due to exposure to contaminated 
blood products. The absence of HCV infections in 
children younger than 5 yo is an undeniable result of 
improvements in the treatment of hemophilia. Methods 
of purification and viral inactivation associated with a 
more effective screening of donors for possible viral 
infections through nucleic acid testing increased the 
safety level of blood products.
The total prevalence of HCV infections (47% in 
patients with HA and 24.2% in those with HB) is 
remarkable. Although reports from 2009-20106 described 
a prevalence of 5%, 85% of the patients had not been 
not tested or did not have HCV test results on their 
medical records. Similarly, a 2011-20125 report also 
revealed a 5% HCV seropositivity, despite describing 
85% of untested patients. In the present cohort, 92% 
of the evaluated patients had information available 
regarding HCV tests. Therefore, the prevalence of 
HCV infections, albeit impressive, is more likely to 
represent the real-life status of this population.
Data regarding HIV infections are also conflicting. 
A report from 2007 showed a prevalence of 4.5% 
for patients with HA and 3.5% for those with HB, 
even though only 30% of the patients had been 
tested7. Another report settled a prevalence of 1% 
for patients with both HA and HB, but 80% of their 
patients lacked screening. The World Federation 
of Hemophilia estimates that around 10% of the 
population with hemophilia is infected with HIV12,13. 
This value is much closer to what was observed in 
our cohort, (7.7% prevalence). Previous reports are 
likely a result of underreporting and testing scarcity.
Musculoskeletal bleeding is the main clinical 
manifestation and cause of morbidity in patients 
with hemophilia. If left untreated, bleeding leads 
to decreased range of motion and joint deformity, 
hampering mobility and culminating in a sedentary 
lifestyle and its consequences. We found at least one 
arthropathy in 52.3% of patients with HA and in 45.6% 
of those with HB, without a significant difference in 
frequency. On the other hand, the literature indicates 
a 3-fold higher risk of arthropathy in patients with 
HA14. Two other studies with adolescents and young 
adults evaluated the number of arthropathies, annual 
average consumption of coagulation factors, frequency 
of bleeding, and radiological findings; their results also 
showed a higher severity of bleeding in patients with 
HA15,16. Notwithstanding, a recent study conducted 
with children with severe and moderate HA and HB 
found no differences regarding age of first exposure 
to coagulation factor, age of first general bleeding, 
and age of first articular bleeding17. This discrepancy 
might be due to the divergent severity criteria and 
methodologies adopted by these studies.
In addition, we found an intuitive relationship 
between increases in disease severity and the number 
of arthropathies, along with a direct association 
between mean factor consumption and the frequency 
of arthropathies. These results suggest that the 
severity of hemophilia is closely related to a residual 
activity of the coagulation factor.
The development of inhibitors is a widely feared 
complication in the treatment of hemophilia and 
correlates with a worse prognosis. There is still 
concern regarding an increased risk of inhibitors 
associated with the early exposure to coagulation 
factors performed in primary prophylaxis, as well as 
with the use of recombinant products when compared 
to plasma-derived. Testing for inhibitors is fundamental 
when monitoring patients with hemophilia. In fact, 
85% of our population was tested and most had no 
detectable inhibitors (86.5% for HA and 96% for HB). 
The testing rate and prevalence of inhibitors were 
higher in our study when compared to those reported 
by the Profile of Hereditary Coagulopathies in Brazil 
published in 2007 by the state of Rio Grande do 
Sul7. In this profile, which compiles data from 2005 
and 2006, only 7 individuals with HA were tested for 
inhibitors, corresponding to 1.8% of the 384-patient 
population; all had negative inhibitor results. On the 
following profile, referring to 2011-2012, these rates 
were improved: 72% of patients with HA were tested, 
with 5.95% of positive results regarding all patients. 
Among patients with HB, 51 had been tested and 
the proportion of patients presenting inhibitors was 
2.38%5. The detection of inhibitors impacts treatment 
and increases its cost. When comparing our results 
to the reports of subsequent years5-7, we might 
assume that the reduction in inhibitor detection rates 
was mainly due to underreporting, since there was 
an increase in investment in programs to promote 
health in this population.
In the 2000s, the National Program of Inherited 
Bleeding Disorders of the Brazilian Ministry of 
Health reached the acquisition of the internationally 
recommended number of coagulation factor units per 
capita. According to the 2011 profile, the average 
consumption of factors VIII and IX was, respectively, 
31,069 IUs and 32,105 IUs per patient. In 2012, there 
were marked increases of 21.1% and 15.4% in the 
mean consumption of factors VII and IX per patient, 
respectively. For the same level of correction, the 
number of IUs required for treating HB is twice that 
required for treating HA; therefore, the proportion of 
coagulation factor consumption by patients with HB 
is clearly inferior. These findings also correlate with 
those reported by other studies18.
Some limitations of this study should not be 
overseen. As a retrospective study with data 
collected from medical records, missing information 
is an inherent bias. Indeed, the National Program of 
Inherited Bleeding Disorders in Brazil had an important 
percentage of missing data and underreporting5-7.
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Our results delineate the improvements in hemophilia 
treatment before and at the moment of program 
implementation. Unfortunately, it is reasonable to 
assume that underreporting has increased along 
the years, which renders the evaluation of the true 
impact of the initiative (and of the areas in need for 
improvement) a great challenge. It is important to 
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reinforce that these data were obtained in the pre-
prophylaxis era, and an ongoing study aims to verify 
the impact of this intervention. The awareness of 
health care workers on the importance of reporting 
hemophilia cases and treatment outcomes is crucial 
for extracting reliable information that underpins 
decision making on hemophilia in Brazil.
